Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Meningococcal vaccines.

Jens U Rüggeberg1, Andrew J Pollard

  • 1Department of Child Health and Vaccine Institute, St George's Hospital Medical School, London, UK.

Paediatric Drugs
|September 2, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Divergent trajectories of antiviral memory after SARS-CoV-2 infection.

Nature communications·2022
Same author

Genetic Susceptibility to Enteric Fever in Experimentally Challenged Human Volunteers.

Infection and immunity·2022
Same author

Public engagement during a typhoid conjugate vaccine trial in Lalitpur, Nepal- experience, challenges and lessons learnt.

Human vaccines & immunotherapeutics·2022
Same author

Viral vectors expressing group B meningococcal outer membrane proteins induce strong antibody responses but fail to induce functional bactericidal activity.

The Journal of infection·2022
Same author

Durability of ChAdOx1 nCoV-19 vaccination in people living with HIV.

JCI insight·2022
Same author

CMV-associated T cell and NK cell terminal differentiation does not affect immunogenicity of ChAdOx1 vaccination.

JCI insight·2022
Same journal

Recent Advances in the Pharmacological Management of Pediatric Spondyloarthritis.

Paediatric drugs·2026
Same journal

Molluscum Contagiosum Treatments in Children: A Systematic Review with Network Meta-Analysis.

Paediatric drugs·2026
Same journal

Real-World Systemic Treatment Patterns and Outcomes of Children With Severe Alopecia Areata: A French Nationwide Study (ESTAPED ohort).

Paediatric drugs·2026
Same journal

Epinephrine Underuse for Anaphylaxis in Infants and Toddlers: A Practical Review for Pediatricians.

Paediatric drugs·2026
Same journal

Risks of Undertreatment and Overtreatment in Pediatric Inflammatory Bowel Disease: Navigating the Balance.

Paediatric drugs·2026
Same journal

Discontinuing Colchicine in Pediatric Familial Mediterranean Fever: Real-Life Experience from a Long-Term Follow-Up Cohort.

Paediatric drugs·2026
See all related articles

Meningococcal vaccines targeting serogroups A, C, Y, and W135 are advancing, particularly conjugate vaccines effective in children. However, preventing serogroup B meningococcal disease remains a significant challenge, with ongoing research into novel vaccine candidates.

Area of Science:

  • Microbiology
  • Immunology
  • Vaccinology

Background:

  • Meningococcal disease is a severe infection, especially in young individuals, necessitating effective prevention strategies.
  • The antigenic variability of Neisseria meningitidis complicates vaccine development.
  • Existing polysaccharide vaccines have limitations in young children, addressed by conjugate technology.

Purpose of the Study:

  • To review the progress and challenges in developing meningococcal vaccines.
  • To highlight the success of conjugate vaccines for certain serogroups and the difficulties in preventing serogroup B disease.

Main Methods:

  • Review of existing meningococcal polysaccharide and conjugate vaccines.
  • Discussion of outer membrane vesicle and recombinant protein-based vaccines for serogroup B.

Related Experiment Videos

  • Exploration of novel vaccine candidates, including genomic and in silico approaches.

    • Main Results:

    • Conjugate vaccines for serogroups A, C, Y, and W135 are effective and increasingly used.
    • Serogroup B vaccine development faces challenges due to strain-specific protection and limited understanding of natural immunity.
    • Various novel vaccine candidates are under investigation, showing promise in animal models.

    Conclusions:

    • Glycoconjugate vaccines have significantly improved protection against specific meningococcal serogroups, especially in children.
    • Developing a broadly protective vaccine against serogroup B remains a critical unmet need in meningococcal disease prevention.
    • Continued research into novel antigens and understanding natural immunity mechanisms is essential for future vaccine advancements.